Artículos del autor

solaci

Chronic Coronary Syndromes

EuroCTO: Safety and Benefit at 3 Years

Chronic total occlusions (CTOs) account for approximately 15-20% of patients with stable coronary artery disease. This field...
solaci -
Structural heart disease

SCOPE I Results at 3 Years: ACURATE Neo vs. SAPIEN 3

Transcatheter aortic valve implantation (TAVI) has become the standard treatment for elderly patients with severe symptomatic aortic...
solaci -
Acute coronary syndromes

STREAM-2: Reduced Dosage of Tenecteplase for Patients over 60 Years Old

Reduced dosage of tenecteplase in elderly patients undergoing a pharmaco-invasive strategy. Delays in achieving timely reperfusion in patients...
solaci -
Femoropopliteal

Device Effectiveness for Femoropopliteal Artery Disease Treatment: Analysis of K-VIS ELLA Registry

Endovascular treatment of lesions in femoropopliteal territory (FPA) has become the main therapeutic option, seeing as it...
solaci -
SOLACI-SBHCI 2023 News

International Joint Sessions at SOLACI-SBHCI 2023

The most important Scientific Societies in the world will be present at the SOLACI-SBHCI 2023 Congress. Discover...
solaci -
ProEducar

ProEducar-SOLACI Fellows Course 2023 – Participate for a grant for the SCAI Fellows Course

For the thirteenth consecutive year, we will be hosting an educational excellence course for interventionalists in training...
solaci -
Acute coronary syndromes

ABSORB IV – Improving Bioresorbable Scaffolds: A Long Road

5-year followup of bioresorbable scaffolds in selected and better prepared lesions (ABSORB IV).  Historically, when comparing previously used...
solaci -
Acute coronary syndromes

No Reflow after Primary PCI in STEMI: An Angiographic Analysis of the TOTAL Study

In the early days of percutaneous coronary intervention (PCI) in patients with ST elevation acute myocardial infarction...
solaci -